Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia.

However, a nonsignificant trend toward improvement in relapse‐free survival with azacitidine was observed in the subgroup of patients who received at least 9 cycles of treatment.

also in 5,406 other papers

The 5‐year OS rate showed a trend for improvement with sorafenib; it was 61% with sorafenib vs 50% with placebo. 55 In contrast, dasatinib did not improve DFS when used as single‐agent maintenance therapy in a phase 2 study in 26 patients (7 with KIT mutations; 6 with FLT 3 mutations; aged 18‐60 years) with core binding factor‐AML in first CR. 56 Maintenance therapy with immune‐mediated therapies is being investigated in clinical trials.

also in 53,322 other papers